Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease

Jacek RyszWAM University Hospital of Lodz, Department of Nephrology, Hypertension and Family Medicine, Zeromskiego 113, 90-549 Lodz, Poland+48 42 639 37 50; +48 42 639 37 50; [email protected];Medical University of Lodz, Healthy Aging Research Center, Lodz, Poland

, MD PhD FASN (Professor) ,

Anna Gluba-BrzózkaMedical University of Lodz, Healthy Aging Research Center, Lodz, Poland;WAM University Hospital of Lodz, Department of Nephrology, Hypertension and Family Medicine, Lodz, Poland

Dimitri P MikhailidisUniversity College London (UCL), University College London Medical School, Department of Clinical Biochemistry, Royal Free Campus, London, UK

Maciej BanachWAM University Hospital of Lodz, Department of Nephrology, Hypertension and Family Medicine, Lodz, Poland;University College London (UCL), University College London Medical School, Department of Clinical Biochemistry, Royal Free Campus, London, UK;Medical University of Lodz, Department of Hypertension, Lodz, Poland

Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date